Pharmacy Articles

Pharmacy

sponsor
Become a Member Today!
Register
Email:


Password:

Remember me
Forgot your Password?
Invite Code?
Article ID

Your Article Summary

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Jackson LR et al. – Despite early promise as the "ideal SERM", results from a phase III trial have relegated arzoxifene to research in breast cancer prevention and osteoporosis treatment.

Related Articles

Contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers
Journal of Clinical Oncology, 10/29/09    Relevance Score: 74%

Advanced Breast Cancer and Breast Cancer Mortality in Randomized Controlled Trials on Mammography Screening
Journal of Clinical Oncology, 11/09/09    Relevance Score: 72%

Adipocyte fatty acid-binding protein as a novel prognostic factor in obese breast cancer patients
Breast Cancer Research and Treatment, 10/27/09    Relevance Score: 72%

Underweight and breast cancer recurrence and death: A report from the Korean breast cancer society
Journal of Clinical Oncology, 10/08/09    Relevance Score: 72%

Reduced prediagnostic 25-hydroxyvitamin D levels in women with breast cancer: a nested case-control study
Cancer Epidemiology, Biomarkers & Prevention, 10/01/09    Relevance Score: 72%

Today in Other Drugs...keeping you current

Persistence with injectable antidiabetic agents in members with type 2 diabetes in a commercial managed care organization
Current Medical Research and Opinion, 11/25/09

Anti-relapse medications: Preclinical models for drug addiction treatment
Pharmacology & Therapeutics, 11/25/09

Glibenclamide-related excess in total and cardiovascular mortality risks: Data from large Ukrainian observational cohort study
Diabetes Research and Clinical Practice, 11/25/09


Sponsor

Article Search

Keyword:

Search:

Published within

Sort By:
Date
Relevance


Sponsor

Send this Summary to a Colleague

Enter email address